If stocks are so expensive, why are there so many mergers? That was the question Jim Cramer posed to his Mad Money viewers Monday. While some companies are too big to be acquired, there are thousands that can be bought and many of them are.

Just today we learned that Charles Schwab (SCHW) - Get Report is paying $26 billion to snap up rival TD Ameritrade (AMTD) - Get Report , giving it the scale it needs to stay relevant and competitive. We also learned that LVMH will add Tiffany (TIF) - Get Report to its portfolio of high-end brands. Cramer said LVMH "gets it" when it comes to selling luxury goods in today's tech savvy world.

There are several sectors that are ripe for consolidation, Cramer said. There are too many retailers out there, which makes Foot Locker (FL) - Get Report and Nordstrom (JWN) - Get Report both attractive. We also have too many software and cybersecurity companies, too many biotechs, too many banks and fin-tech companies. The online food delivery space is in desperate need of consolidation, as are the semiconductors, although many of those will require Chinese approval.

Mergers are a sign of a healthy market, Cramer said, which is why those who say stocks are too expensive aren't valuing companies the way a potential acquirer would.

Cramer and the AAP team are looking at everything from earnings and tariffs to the Federal Reserve. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts Plus.

Executive Decision: Bristol-Myers Squibb

For his "Executive Decision" segment, Cramer spoke with Giovanni Caforio, CEO of Bristol-Myers Squibb (BMY) - Get Report , the drugmaker that just closed on its acquisition of Celgene.

Caforio explained that as a combined company, Bristol Myers and Celgene can help more patients with strong positions in the treatment of cancer and cardiovascular disease. The new Bristol Myers, he said, is a growth company that's well positioned to succeed.

Bristol Myers is currently in the process of launching seven new drugs, Caforio said, and the pipeline includes 50 drugs that are currently in phase one or phase two testing. He had high hopes for Eliquis, a treatment for atrial fibrillation. He said Eliquis is taking share for those already being treated for A-fib, but there are many patients that have been diagnosed but aren't yet being treated, and many more who have not yet been diagnosed.

When asked about drug pricing, Caforio said that access to affordable medication is an important issue. There needs to be policy changes to make drugs more affordable, he said, and if the industry works together with regulators, they can get more treatments into the hands of more patients. 

On Real Money, Cramer keys in on the companies and CEOs he knows best. Get more of his insights with a free trial subscription to Real Money.

Executive Decision: PVH

In his second "Executive Decision" segment, Cramer sat down with Manny Chirico, chairman and CEO of apparel maker PVH (PVH) - Get Report , which just posted a strong quarter with a top- and bottom-line earnings beat.

Chirico said that Hong Kong and greater China remains a challenging market for PVH. In Europe, however, sales are strong, with Tommy Hilfiger performing exceptionally well and the Calvin Klein brand also growing.

In the U.S., apparel remains a mixed bag, Chirico said. There hasn't been much cold weather to spur people into buying winter apparel yet, and the Heritage brand remains challenged, particularly at mall-based retailers like Macy's (M) - Get Report , Kohl's Stores (KSS) - Get Report and JCPenney (JCP) - Get Report . Heritage only represents 10% to 12% of PVH sales, Chirico added, and he thinks the damage has been contained.

Turning to the topic of trade, Chirico said he understands the uncertainty in the share price and why the stock sells for just 10 times earnings. He said it's almost Dec. 1 and they have no idea what tariffs they will be paying on Jan. 1. That didn't stop Chirico from personally buying $10 million worth of stock earlier this year, however. He said he's taking a long-term view and is confident the company will be in great shape. 

Off the Tape: Carbon

In his "Off The Tape" segment, Cramer sat down with Ellen Kullman, president and CEO, and Joseph DeSimone, executive chairman, of the privately-held Carbon, a company working on the next-generation of 3D printing technology.

For years, 3D printing has been billed as the future of manufacturing, but in reality, the technology has been used primarily for prototyping and not actual manufacturing. But DeSimone said Carbon has finally "cracked the code," making the process faster, with new materials and a new business model that makes manufacturing a reality.

Carbon is already manufacturing auto parts and electrical connectors, DeSimone said, and the company has a partnership with Johnson & Johnson (JNJ) - Get Report for the development of a mesh to be used for post-surgical applications to help patients heal their wounds.

Kullman, formerly of DuPont (DD) - Get Report , said that Carbon has many exciting end-market opportunities.

U-Turn for Uber?

In his "No-Huddle Offense" segment, Cramer said Uber (UBER) - Get Report may finally be done playing defense and its shares might actually be worth buying.

Cramer said Monday's news that the company has run afoul of regulators in London initially tanked the stock, but shares quickly rebounded. The situation might not be as bad as many people feared, he said, and the service will remain active pending appeal.

Beyond London, however, Cramer said the good news at Uber is the stock's lockup period is now over and those who wanted to sell likely already have. Additionally, the company might be willing to shed underperforming businesses, like UberEats, and focus on making its core business profitable. 

Lightning Round 

In the Lightning Round, Cramer was bullish on Copart (CPRT) - Get Report , CarGurus (CARG) - Get Report , Costco (COST) - Get Report and Alteryx (AYX) - Get Report .

Cramer was bearish on Sonos (SONO) - Get Report , Elastic (ESTC) - Get Report , Molson Coors (TAP) - Get Report and Pivotal Software (PVTL) - Get Report .

Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in KSS, JNJ.